🚀 VC round data is live in beta, check it out!
BioCryst Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioCryst Pharma and similar public comparables like Jinyu Bio-Technology Co., Anhui Anke Biotechnology, Bavarian Nordic, Nektar Therapeutics and more.
BioCryst Pharma Overview
About BioCryst Pharma
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Founded
1991
HQ
Employees
580
Website
Sectors
Financials (LTM)
EV
$3B
BioCryst Pharma Financials
BioCryst Pharma reported last 12-month revenue of $808M.
In the same LTM period, BioCryst Pharma generated $791M in gross profit and $202M in net income.
Revenue (LTM)
BioCryst Pharma P&L
In the most recent fiscal year, BioCryst Pharma reported revenue of $875M and EBITDA of $348M.
BioCryst Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $808M | XXX | $875M | XXX | XXX | XXX |
| Gross Profit | $791M | XXX | $856M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | — | XXX | $348M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $202M | XXX | $264M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | — | — | $337M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioCryst Pharma Stock Performance
BioCryst Pharma has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
BioCryst Pharma's stock price is $9.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | 0.0% | XXX | XXX | XXX | $1.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioCryst Pharma Valuation Multiples
BioCryst Pharma trades at 3.1x EV/Revenue multiple, and 7.3x EV/EBITDA.
EV / Revenue (LTM)
BioCryst Pharma Financial Valuation Multiples
As of April 20, 2026, BioCryst Pharma has market cap of $2B and EV of $3B.
Equity research analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioCryst Pharma has a P/E ratio of 11.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBIT | 9.4x | XXX | 7.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | 3.0x | XXX | XXX | XXX |
| P/E | 11.8x | XXX | 9.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioCryst Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioCryst Pharma Margins & Growth Rates
BioCryst Pharma's revenue in the last 12 month declined by (16%).
BioCryst Pharma's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.9M for the same period.
BioCryst Pharma's rule of 40 is (18%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioCryst Pharma's rule of X is (56%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioCryst Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (16%) | XXX | (26%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (85%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (18%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (56%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioCryst Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioCryst Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jinyu Bio-Technology Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Bavarian Nordic | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ultragenyx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioCryst Pharma M&A Activity
BioCryst Pharma acquired XXX companies to date.
Last acquisition by BioCryst Pharma was on XXXXXXXX, XXXXX. BioCryst Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioCryst Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioCryst Pharma Investment Activity
BioCryst Pharma invested in XXX companies to date.
BioCryst Pharma made its latest investment on XXXXXXXX, XXXXX. BioCryst Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioCryst Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioCryst Pharma
| When was BioCryst Pharma founded? | BioCryst Pharma was founded in 1991. |
| Where is BioCryst Pharma headquartered? | BioCryst Pharma is headquartered in United States. |
| How many employees does BioCryst Pharma have? | As of today, BioCryst Pharma has over 580 employees. |
| Who is the CEO of BioCryst Pharma? | BioCryst Pharma's CEO is Charles K. Gayer. |
| Is BioCryst Pharma publicly listed? | Yes, BioCryst Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of BioCryst Pharma? | BioCryst Pharma trades under BCRX ticker. |
| When did BioCryst Pharma go public? | BioCryst Pharma went public in 1994. |
| Who are competitors of BioCryst Pharma? | BioCryst Pharma main competitors are Jinyu Bio-Technology Co., Anhui Anke Biotechnology, Bavarian Nordic, Nektar Therapeutics. |
| What is the current market cap of BioCryst Pharma? | BioCryst Pharma's current market cap is $2B. |
| What is the current revenue of BioCryst Pharma? | BioCryst Pharma's last 12 months revenue is $808M. |
| What is the current revenue growth of BioCryst Pharma? | BioCryst Pharma revenue growth (NTM/LTM) is (16%). |
| What is the current EV/Revenue multiple of BioCryst Pharma? | Current revenue multiple of BioCryst Pharma is 3.1x. |
| Is BioCryst Pharma profitable? | Yes, BioCryst Pharma is net-income-positive (as of the last 12 months). |
| What is the current net income of BioCryst Pharma? | BioCryst Pharma's last 12 months net income is $202M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.